Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report.

Randhawa M, Gaughran G, Archer C, Pavli P, Morey A, Ali S, Yip D.

World J Clin Oncol. 2019 Oct 24;10(10):350-357. doi: 10.5306/wjco.v10.i10.350.

2.

Quality of Care in Inflammatory Bowel Disease: Actual Health Service Experiences Fall Short of the Standards.

Mikocka-Walus A, Massuger W, Knowles SR, Moore GT, Buckton S, Connell W, Pavli P, Raven L, Andrews JM.

Intern Med J. 2019 Nov 9. doi: 10.1111/imj.14683. [Epub ahead of print]

PMID:
31707751
3.

Haemoperitoneum Due to Spontaneous Rupture of a Liver Metastasis.

Dolapsakis C, Pavli P, Panagopoulos A, Tavernaraki E, Varnavas G, Papapostolou A, Machairas A.

Eur J Case Rep Intern Med. 2019 Jun 26;6(7):001142. doi: 10.12890/2019_001142. eCollection 2019.

4.

Crohn's & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia.

Massuger W, Moore GTC, Andrews JM, Kilkenny MF, Reyneke M, Knowles S, Purcell L, Alex G, Buckton S, Page AT, Stocks N, Cameron D, Manglaviti F, Pavli P.

Intern Med J. 2019 Jul;49(7):859-866. doi: 10.1111/imj.14187.

PMID:
30525299
5.

Guided cell adhesion, orientation, morphology and differentiation on silicon substrates photolithographically micropatterned with a cell-repellent cross-linked poly(vinyl alcohol) film.

Bourkoula A, Mavrogonatou E, Pavli P, Petrou PS, Douvas AM, Argitis P, Kletsas D, Kakabakos SE.

Biomed Mater. 2018 Oct 26;14(1):014101. doi: 10.1088/1748-605X/aae7ba.

PMID:
30362459
6.

The microbiome of Crohn's disease aphthous ulcers.

O'Brien CL, Kiely CJ, Pavli P.

Gut Pathog. 2018 Oct 10;10:44. doi: 10.1186/s13099-018-0265-6. eCollection 2018.

7.

Prevalence of Yersinia Species in the Ileum of Crohn's Disease Patients and Controls.

Le Baut G, O'Brien C, Pavli P, Roy M, Seksik P, Tréton X, Nancey S, Barnich N, Bezault M, Auzolle C, Cazals-Hatem D, Viala J, Allez M; REMIND GROUP, Hugot JP, Dumay A.

Front Cell Infect Microbiol. 2018 Sep 21;8:336. doi: 10.3389/fcimb.2018.00336. eCollection 2018.

8.

The microbiome of translocated bacterial populations in patients with and without inflammatory bowel disease.

Kiely CJ, Pavli P, O'Brien CL.

Intern Med J. 2018 Nov;48(11):1346-1354. doi: 10.1111/imj.13998.

PMID:
29893034
9.

Inflammatory bowel disease-related fatigue is correlated with depression and gender.

Keightley P, Reay RE, Pavli P, Looi JC.

Australas Psychiatry. 2018 Oct;26(5):508-513. doi: 10.1177/1039856218772245. Epub 2018 May 8.

PMID:
29737197
10.

Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.

Chan W, Lynch N, Bampton P, Chang J, Chung A, Florin T, Hetzel DJ, Jakobovits S, Moore G, Pavli P, Radford-Smith G, Thin L, Baraty B, Haifer C, Yau Y, Leong RWL.

Eur J Gastroenterol Hepatol. 2018 Jul;30(7):735-740. doi: 10.1097/MEG.0000000000001150.

PMID:
29727386
11.

The role of inflammation in temporal shifts in the inflammatory bowel disease mucosal microbiome.

Kiely CJ, Pavli P, O'Brien CL.

Gut Microbes. 2018 Nov 2;9(6):477-485. doi: 10.1080/19490976.2018.1448742. Epub 2018 Sep 5.

12.

Within-host evolution versus immigration as a determinant of Escherichia coli diversity in the human gastrointestinal tract.

Dixit OVA, O'Brien CL, Pavli P, Gordon DM.

Environ Microbiol. 2018 Mar;20(3):993-1001. doi: 10.1111/1462-2920.14028. Epub 2017 Dec 29.

PMID:
29266651
13.

Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.

Peer FC, Miller A, Pavli P, Subramaniam K.

Intern Med J. 2017 Dec;47(12):1445-1448. doi: 10.1111/imj.13637.

PMID:
29224199
14.

Genital Granulomatosis in Male and Female Patients With Crohn's Disease: Clinical Presentation and Treatment Outcomes.

Dederichs F, Iesalnieks I, Sladek M, Tzivinikos C, Hansen R, Muñoz C, Pavli P, Cavicchi M, Abitbol V, Rahier JF, Vavricka S, Katsanos K, Domènech E; ECCO-CONFER investigators.

J Crohns Colitis. 2018 Jan 24;12(2):197-203. doi: 10.1093/ecco-jcc/jjx131.

PMID:
29029098
15.

Fine-Scale Structure Analysis Shows Epidemic Patterns of Clonal Complex 95, a Cosmopolitan Escherichia coli Lineage Responsible for Extraintestinal Infection.

Gordon DM, Geyik S, Clermont O, O'Brien CL, Huang S, Abayasekara C, Rajesh A, Kennedy K, Collignon P, Pavli P, Rodriguez C, Johnston BD, Johnson JR, Decousser JW, Denamur E.

mSphere. 2017 May 31;2(3). pii: e00168-17. doi: 10.1128/mSphere.00168-17. eCollection 2017 May-Jun.

16.

Analysis of the human monocyte-derived macrophage transcriptome and response to lipopolysaccharide provides new insights into genetic aetiology of inflammatory bowel disease.

Baillie JK, Arner E, Daub C, De Hoon M, Itoh M, Kawaji H, Lassmann T, Carninci P, Forrest AR, Hayashizaki Y; FANTOM Consortium, Faulkner GJ, Wells CA, Rehli M, Pavli P, Summers KM, Hume DA.

PLoS Genet. 2017 Mar 6;13(3):e1006641. doi: 10.1371/journal.pgen.1006641. eCollection 2017 Mar.

17.

Comparative genomics of Crohn's disease-associated adherent-invasive Escherichia coli.

O'Brien CL, Bringer MA, Holt KE, Gordon DM, Dubois AL, Barnich N, Darfeuille-Michaud A, Pavli P.

Gut. 2017 Aug;66(8):1382-1389. doi: 10.1136/gutjnl-2015-311059. Epub 2016 Apr 20.

18.

Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.

Kiely CJ, Subramaniam K, Platten J, Pavli P.

Intern Med J. 2016 May;46(5):616-9. doi: 10.1111/imj.13057.

PMID:
27170239
19.

Placental involvement by non-Hodgkin lymphoma in a Crohn disease patient on long-term thiopurine therapy.

Chen G, Crispin P, Cherian M, Dahlstrom JE, Sethna FF, Kaye G, Pavli P, Subramaniam K.

Intern Med J. 2016 Jan;46(1):102-5. doi: 10.1111/imj.12957.

PMID:
26813900
20.

Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors.

Subramaniam K, Tymms K, Shadbolt B, Pavli P.

Intern Med J. 2015 Nov;45(11):1154-60. doi: 10.1111/imj.12891.

PMID:
26337851
21.

Gut feelings 1. Mind, mood and gut in irritable bowel syndrome: approaches to psychiatric care.

Keightley P, Pavli P, Platten J, Looi JC.

Australas Psychiatry. 2015 Aug;23(4):403-6. doi: 10.1177/1039856215590033. Epub 2015 Jul 6. Review.

PMID:
26148736
22.

Gut feelings 2. Mind, mood and gut in inflammatory bowel disease: approaches to psychiatric care.

Keightley P, Pavli P, Platten J, Looi JC.

Australas Psychiatry. 2015 Aug;23(4):407-10. doi: 10.1177/1039856215590034. Epub 2015 Jun 30. Review.

PMID:
26133813
23.

Escherichia coli diversity in the lower intestinal tract of humans.

Gordon DM, O'Brien CL, Pavli P.

Environ Microbiol Rep. 2015 Aug;7(4):642-8. doi: 10.1111/1758-2229.12300.

PMID:
26034010
24.

Enhancing Cryptosporidium parvum recovery rates for improved water monitoring.

Pavli P, Venkateswaran S, Bradley M, Bridle H.

Chemosphere. 2016 Jan;143:57-63. doi: 10.1016/j.chemosphere.2015.05.021. Epub 2015 May 23.

25.

Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease.

Subramaniam K, Fallon K, Ruut T, Lane D, McKay R, Shadbolt B, Ang S, Cook M, Platten J, Pavli P, Taupin D.

Aliment Pharmacol Ther. 2015 Mar;41(5):419-28. doi: 10.1111/apt.13058. Epub 2015 Jan 8.

26.

Protein-resistant cross-linked poly(vinyl alcohol) micropatterns via photolithography using removable polyoxometalate photocatalyst.

Pavli P, Petrou PS, Douvas AM, Dimotikali D, Kakabakos SE, Argitis P.

ACS Appl Mater Interfaces. 2014 Oct 22;6(20):17463-73. doi: 10.1021/am5053224. Epub 2014 Sep 30.

PMID:
25212665
27.

Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?

Subramaniam K, Yeung D, Grimpen F, Joseph J, Fay K, Buckland M, Talaulikar D, Elijah J, Clarke AC, Pavli P, Moore J.

Intern Med J. 2014 Mar;44(3):287-90. doi: 10.1111/imj.12363. Review.

PMID:
24621284
28.

Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.

Subramaniam K, Richardson A, Dodd J, Platten J, Shadbolt B, Pavli P.

Intern Med J. 2014 May;44(5):464-70. doi: 10.1111/imj.12397.

PMID:
24612209
29.

Detection of bacterial DNA in lymph nodes of Crohn's disease patients using high throughput sequencing.

O'Brien CL, Pavli P, Gordon DM, Allison GE.

Gut. 2014 Oct;63(10):1596-606. doi: 10.1136/gutjnl-2013-305320. Epub 2014 Jan 15.

PMID:
24429583
30.

Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications.

Subramaniam K, Cherian M, Jain S, Latimer M, Corbett M, D'Rozario J, Pavli P.

Intern Med J. 2013 Dec;43(12):1339-42. doi: 10.1111/imj.12287.

PMID:
24330365
31.

Impact of colonoscopy bowel preparation on intestinal microbiota.

O'Brien CL, Allison GE, Grimpen F, Pavli P.

PLoS One. 2013 May 1;8(5):e62815. doi: 10.1371/journal.pone.0062815. Print 2013.

32.

The more the merrier: Faecalibacterium prausnitzii in Crohn's disease.

O'Brien CL, Allison GE, Pavli P.

J Gastroenterol Hepatol. 2013 May;28(5):757-9. doi: 10.1111/jgh.12153. No abstract available.

PMID:
23614339
33.

Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.

Subramaniam K, D'Rozario J, Pavli P.

J Gastroenterol Hepatol. 2013 Jan;28(1):24-30. doi: 10.1111/jgh.12015. Review.

PMID:
23094824
34.

Glatiramer acetate induced hepatotoxicity.

Subramaniam K, Pavli P, Llewellyn H, Chitturi S.

Curr Drug Saf. 2012 Apr;7(2):186-8.

PMID:
22873505
35.

Risk of non-melanoma skin cancer with thiopurine use in inflammatory bowel disease.

Subramaniam K, Pavli P.

J Gastroenterol Hepatol. 2012 Feb;27(2):193-4. doi: 10.1111/j.1440-1746.2011.07030.x. No abstract available.

PMID:
22260282
36.

Foot drop developing during infliximab therapy for inflammatory bowel disease.

Subramaniam K, Hughes A, Pavli P.

Inflamm Bowel Dis. 2013 Feb;19(2):E24-5. doi: 10.1002/ibd.22881. No abstract available.

PMID:
22253031
37.

Should patients be screened for hereditary cancer syndromes before starting anti-TNF-α therapy?

Subramaniam K, Tucker K, Craft P, Pavli P.

Inflamm Bowel Dis. 2011 Nov;17(11):E151-2. doi: 10.1002/ibd.21883. Epub 2011 Aug 30. No abstract available.

PMID:
21987302
38.

Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate.

Subramaniam K, Chitturi S, Brown M, Pavli P.

Inflamm Bowel Dis. 2011 Nov;17(11):E149-50. doi: 10.1002/ibd.21880. Epub 2011 Aug 30. No abstract available.

PMID:
21987301
39.

Effects of bacterial products on enterocyte-macrophage interactions in vitro.

Tyrer PC, Bean EG, Ruth Foxwell A, Pavli P.

Biochem Biophys Res Commun. 2011 Sep 23;413(2):336-41. doi: 10.1016/j.bbrc.2011.08.100. Epub 2011 Aug 27.

PMID:
21893047
40.

Advances in the management of inflammatory bowel disease.

Grimpen F, Pavli P.

Intern Med J. 2010 Apr;40(4):258-64. doi: 10.1111/j.1445-5994.2010.02163.x. Epub 2010 Jan 4. Review.

PMID:
20059603
41.

Journal of Gastroenterology and Hepatology. In this issue.

Chitturi S, Pavli P.

J Gastroenterol Hepatol. 2009 May;24(5):i. doi: 10.1111/j.1440-1746.2009.05937.x. No abstract available.

PMID:
19646008
42.

Rational investigation of upper abdominal pain.

Grimpen F, Pavli P.

Aust Fam Physician. 2008 Aug;37(8):602-7. Review.

PMID:
18704205
43.

Identifying susceptibility to inflammatory bowel diseases: a candidate gene approach, genome-wide association studies, or both?

Pavli P, Summers KM.

J Gastroenterol Hepatol. 2008 Jan;23(1):6-7. doi: 10.1111/j.1440-1746.2007.05237.x. No abstract available.

PMID:
18171338
44.

Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.

Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D; Antibiotics in Crohn's Disease Study Group.

Gastroenterology. 2007 Jun;132(7):2313-9. Epub 2007 Mar 21.

PMID:
17570206
45.

Aspiration in the context of upper gastrointestinal endoscopy.

Thomson A, Tye-Din J, Tonga S, Scott J, McLaren C, Pavli P, Lomas F.

Can J Gastroenterol. 2007 Apr;21(4):223-5.

46.

What may underlie recurrent purpura fulminans?

Kennedy KJ, Walker S, Pavli P, Hallam L, Hemmings C.

Med J Aust. 2007 Apr 2;186(7):373-5.

PMID:
17407438
47.

Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention.

Fisher L, Fisher A, Pavli P, Davis M.

Aliment Pharmacol Ther. 2007 Feb 1;25(3):297-308. Epub 2007 Jan 8.

48.

The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction.

Pierik M, Yang H, Barmada MM, Cavanaugh JA, Annese V, Brant SR, Cho JH, Duerr RH, Hugot JP, McGovern DP, Paavola-Sakki P, Radford-Smith GL, Pavli P, Silverberg MS, Schreiber S, Taylor KD, Vlietinck R; IBD International Genetics Consortium.

Inflamm Bowel Dis. 2005 Jan;11(1):1-7.

PMID:
15674107
49.

NOD2 mutations and Crohn's disease: are Paneth cells and their antimicrobial peptides the link?

Grimm MC, Pavli P.

Gut. 2004 Nov;53(11):1558-60. Review. No abstract available.

50.

CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population.

Cavanaugh JA, Adams KE, Quak EJ, Bryce ME, O'Callaghan NJ, Rodgers HJ, Magarry GR, Butler WJ, Eaden JA, Roberts-Thomson IC, Pavli P, Wilson SR, Callen DF.

Ann Hum Genet. 2003 Jan;67(Pt 1):35-41.

Supplemental Content

Support Center